IL17A and hypertensive disorder: Several studies revealed that EFAs and their metabolites can regulate blood pressure and prevent development of HTN, at least, in part by restoring IL-17 and Treg balance, decreasing the formation of angiotensin-II and suppressing the expression of angiotensin-II receptors [141, 173–181].